Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes?
Tuzun, Dilek; Oguz, Ayten; Aydin, Muhammet Naci; Kurutas, Ergul Belge; Ercan, Onder; Sahin, Murat; Ünsal, Velid; Ceren, Imran; Akçay, Ahmet; Gul, Kamile.
Arch. endocrinol. metab. (Online)
; 62(5): 506-513, Oct. 2018. tab
Artículo
en Inglés
| LILACS | ID: biblio-983799
ABSTRACT
Objective:
Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone and plays a role in the pathogenesis of myocardial hypertrophy. The aim of this study was to evaluate the association of FGF-23 levels with echocardiographic parameters and insulin resistance (IR) in patients with gestational diabetes. Subjects andmethods:
Fifty-four pregnant patients with gestational diabetes mellitus (GDM) (age, 31.12 ± 5.72 years) and 33 healthy pregnant women (age, 29.51 ± 4.92 years) were involved in the study. Fasting insulin, fasting plasma glucose (FPG), lipid profile, oral glucose tolerance test (OGTT), FGF23, echocardiographic parameters, and carotid artery intima-media thickness (CIMT) were evaluated in the two groups.Results:
The two groups were not significantly different in age, sex, body mass index, lipid profile, or blood pressure. Insulin, homeostatic model assessment-insulin resistance (HOMA-IR), FGF-23 levels, CIMT, left ventricular (LV) mass, LV mass index and myocardial performance index (MPI) were significantly higher in the GDM group. HOMA-IR was positively correlated with FGF-23, and insulin was positively correlated with FGF-23. Additionally, FGF-23 was positively correlated with CIMT, LV mass index, and MPI.Conclusion:
Our findings suggest that monitoring serum FGF-23 may be useful as a non-invasive indicator of subclinical atherosclerosis in patients with GDM.
Biblioteca responsable:
BR1.1
Texto completo
Documentos relacionados